Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 13/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604897 | 0.88 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL10749335 | 0.86 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL17663562 | 0.80 | ACHE (0.66) | ACHEALOX15 | |
| SCHEMBL19356087 | 0.79 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL12107388 | 0.78 | SMN1; SMN2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL15249135 | 0.78 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL12537122 | 0.77 | EPHX1 (0.61) | ACHEALOX15 | |
| SCHEMBL12537126 | 0.77 | EPHX1 (0.61) | ACHEALOX15 | |
| SCHEMBL12537124 | 0.77 | EPHX1 (0.61) | ACHEALOX15 | |
| SCHEMBL12537129 | 0.77 | EPHX1 (0.61) | ACHEALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8137700-B2 | Main chain acid-degradable polymers for the delivery of bioactive materials | U.S. DEPARTMENT OF ENERGY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090220615-A1 | Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220615-A1 | Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials | CTSA, GAA, CTSB | CHRNB2 4247/4885CHRNB4 4667/4885CHRNA3 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.